Kane Biotech loses $607,345 in Q3 2025

Executive Summary

• Kane Biotech Inc. reported its third quarter 2025 financial results, showing a significant decline in revenue and gross profit compared to the same period in 2024, primarily due to the termination of an animal health manufacturing agreement and a U.S. distribution agreement.
• The company reported a net loss of $607,345 for Q3 2025, an improvement from the $678,636 net loss in Q3 2024, driven by reduced operating expenses including staff reductions and lower compensation costs.
• Kane Biotech provided a corporate update on its "revyve" product line, highlighting successful enrollment in U.S. clinical case series, presentation of compelling clinical data at major conferences, and the completion of an FDA 510(k) clearance submission for its wound cleanser.

Key Details

• Revenue: Total revenue for Q3 2025 was $8,499, compared to $1,282,698 in Q3 2024. The comparative quarter's revenue was largely driven by an animal health manufacturing agreement (terminated Q1 2025) and a subsequently terminated U.S. distribution agreement for revyve.
• Gross Profit: Gross loss for Q3 2025 was $(5,128), compared to a gross profit of $558,754 in Q3 2024.
• Operating Expenses: Total operating expenses for Q3 2025 were $538,306, down from $1,170,064 in Q3 2024. The reduction is attributed to staff reductions, lower short and long-term compensation, and lower business development costs.
• Net Loss: Net loss for Q3 2025 was $(607,345), compared to $(678,636) in Q3 2024.
• Cash Position: Cash as of September 30, 2025, was $939,062.
• Clinical Trials (Revyve Case Series): Enrolled 28 participants in the U.S. case series studies for revyve antimicrobial wound gel and spray, exceeding the 25-participant target. Enrollment continues to build a larger patient database.
• Clinical Data Presentations:
  • Presented data at the Symposium on Advanced Wound Care (SAWC) fall conference in September 2025.
  • Presented new clinical data at The Diabetic Foot Conference (DFCon 2025) in October 2025. Results showed an average 97% area wound reduction in four weeks and 100% diabetic wound closure in less than 12 weeks.
  • Presented preclinical data at the Southern Region Burn Conference (October/November 2025) showing a six-log reduction in microbial load within 30 minutes and sustained antibiofilm activity for a minimum of seven days.
• Regulatory & Commercial Updates:
  • Completed FDA 510(k) clearance submission for revyve antimicrobial wound cleanser.
  • Revyve antimicrobial wound gel and spray are U.S. FDA 510(k) cleared.
  • Revyve antimicrobial wound gel is Health Canada approved.
  • Company is rebuilding the U.S. distributor and sales agent network with non-exclusive partners.

Notable Quotes

• "Kane Biotech is making material progress with our U.S. case series on the revyve wound care gel that has exceeded enrollment targets and is producing compelling clinical data that has been presented at industry conferences," said Dr. Robert Huizinga, interim CEO. "Doing so underpins our efforts to rebuild the U.S. distributor network and launch revyve in Canada which reflects our commitment to delivering innovative, high-quality solutions that improve patient outcomes."